News Related to Ezetimibe

Related coverage linked through entity extraction aliases.

NewAmsterdam Pharma reports Q1 results, keeps obicetrapib regulatory and Phase 3 timelines

May 13, 2026

NewAmsterdam Pharma said regulatory decisions on obicetrapib in Europe, the UK and Switzerland remain expected in 2H26. PREVAIL interim analysis is planned for 4Q2026, with a result expected in 1Q2027.

Merck to Present Cardio-Pulmonary Pipeline Data at ACC.26, Including Phase 3 Enlicitide Results

Mar 17, 2026

Merck will present late-breaking clinical data from its cardio-pulmonary pipeline at ACC.26, including positive Phase 3 results for enlicitide, an investigational oral PCSK9 inhibitor, and Phase 2 data for WINREVAIR in heart failure patients.